Patents by Inventor Rachel Kent

Rachel Kent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACTRIIB BINDING AGENTS AND USES THEREOF
    Publication number: 20220098309
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Application
    Filed: April 30, 2021
    Publication date: March 31, 2022
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • ACTRIIB BINDING AGENTS AND USES THEREOF
    Publication number: 20190023797
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Application
    Filed: August 3, 2018
    Publication date: January 24, 2019
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • ACTRIIB BINDING AGENTS AND USES THEREOF
    Publication number: 20180051088
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Application
    Filed: April 3, 2017
    Publication date: February 22, 2018
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • Polynucleotides encoding an actriib antibody
    Patent number: 9624301
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: April 18, 2017
    Assignees: Acceleron Pharma Inc., Dyax Corp.
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • POLYNUCLEOTIDES ENCODING AN ACTRIIB ANTIBODY
    Publication number: 20160347845
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • Polynucleotides encoding an actriib antibody
    Patent number: 9403910
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 2, 2016
    Assignees: Acceleron Pharma Inc., Dyax Corporation
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • ACTRIIB BINDING AGENTS AND USES THEREOF
    Publication number: 20150030606
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Application
    Filed: October 7, 2014
    Publication date: January 29, 2015
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • Method of detection of neutralizing anti-actriib antibodies
    Patent number: 8765385
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: July 1, 2014
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • ACTRIIB BINDING AGENTS AND USES THEREOF
    Publication number: 20130108650
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Application
    Filed: October 27, 2011
    Publication date: May 2, 2013
    Applicant: Acceleron Pharma, Inc.
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS
    Publication number: 20070259417
    Abstract: In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained.
    Type: Application
    Filed: May 7, 2007
    Publication date: November 8, 2007
    Applicant: Dyax Corp.
    Inventors: Robert Ladner, Sonia Guterman, Bruce Roberts, William Markland, Arthur Ley, Rachel Kent
  • ITI-D1 Kunitz domain mutants as hNE inhibitors
    Publication number: 20060134087
    Abstract: Mutants of Kunitz domain 1 (ITI-D1) of human inter-?-trypsin inhibitor (ITI), are useful as inhibitors of human neutrophil elastase. Mutants characterized by one or more of the following substitutions (numbered to correspond to bovine pancreatic trypsin inhibitor, the archetypal Kunitz domain) are of particular interest: (a) Val15 or Ile15, (b) Ala16, (c) Phe18, (d) Pro19, (e) Arg1, (f) Pro2, and/or (g) Phe4.
    Type: Application
    Filed: October 18, 2005
    Publication date: June 22, 2006
    Applicant: Dyax Corp.
    Inventors: Arthur Ley, Sonia Guterman, William Markland, Rachel Kent, Bruce Roberts, Robert Ladner
  • Directed evolution of disulfide-bonded micro-proteins
    Publication number: 20060084113
    Abstract: In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained.
    Type: Application
    Filed: July 31, 2002
    Publication date: April 20, 2006
    Inventors: Robert Ladner, Sonia Guterman, Bruce Roberts, William Markland, Arthur Ley, Rachel Kent